phrykt

Gyre Therapeutics, Inc. (GYRE): who owns it and who trades it

As of Nov 16, 2026, GYRE insiders reported 18 open-market sales worth $953K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Weiguo Ye (Chief Operating Officer), with $870K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling GYRE Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns GYRE

59 funds and institutions reported GYRE shares worth $58.3M at the end of Q2 2026, about 9% of the company. The largest holder is HSG Holding Ltd with 3.9%.

Funds and institutions (13F) 9%Everyone else 91%

10 largest owners, by share of the company

HSG Holding Ltd3.9%
BlackRock, Inc.1.0%
Octagon Capital Advisors LP1.0%
Vanguard Capital Management LLC0.9%
Geode Capital Management, LLC0.5%
State Street Corp0.3%
Charles Schwab Investment Management Inc0.2%
Sixth Street Partners Management Company, L.P.0.2%
Northern Trust Corp0.2%
SBI Securities Co., Ltd.0.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
HSG Holding Ltd3.75M3.87%$24.7MNew
BlackRock, Inc.993,9431.03%$6.6M+31%
Octagon Capital Advisors LP954,4160.98%$6.3MNew
Vanguard Capital Management LLC876,9270.90%$5.8M-11%
Geode Capital Management, LLC532,9500.55%$3.5M+24%
State Street Corp245,4020.25%$1.6M+13%
Charles Schwab Investment Management Inc184,2860.19%$1.2M+12%
Sixth Street Partners Management Company, L.P.184,2860.19%$1.2MNew
Northern Trust Corp169,5370.17%$1.1M+27%
SBI Securities Co., Ltd.166,7500.17%$1.1M-2%
Vanguard Fiduciary Trust Co151,0730.16%$996K+10%
Vanguard Portfolio Management LLC123,9530.13%$817K+78%
Goldman Sachs Group Inc86,2350.09%$568K+18%
Bank of New York Mellon Corp62,7500.06%$414K+45%
Morgan Stanley41,6910.04%$275K+382%
Strs Ohio25,8000.03%$170K+22%
Dimensional Fund Advisors LP25,2680.03%$167KNo change
Alliancebernstein L.P.24,5900.03%$171K+13%
Nuveen, LLC24,5050.03%$161KNew
UBS Group AG18,7630.02%$124K-11%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, GYRE insiders reported $0 of open-market purchases and $953K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$953K
18 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jun 18, 2026
Filed Jun 22, 2026

Purchases and sales by month

$519K$519KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 18, 2026Weiguo YeChief Operating OfficerSale3,000$6.35$19.1KForm 4
Jun 11, 2026Weiguo YeChief Operating OfficerSale2,800$6.17$17.3KForm 4
Jun 10, 2026Weiguo YeChief Operating OfficerSale5,000$6.24$31.2KForm 4
Jun 10, 2026Weiguo YeChief Operating OfficerSale6,418$6.21$39.9KForm 4
Jun 9, 2026Weiguo YeChief Operating OfficerSale3,000$6.15$18.4KForm 4
Jun 9, 2026Weiguo YeChief Operating OfficerSale14,500$6.14$89KForm 4
Jun 5, 2026Weiguo YeChief Operating OfficerSale15,401$6.40$98.6KForm 4
Jun 4, 2026Weiguo YeChief Operating OfficerSale19,575$6.13$120KForm 4
May 26, 2026Weiguo YeChief Operating OfficerSale4,000$6.10$24.4KForm 4
May 22, 2026Weiguo YeChief Operating OfficerSale3,500$6.08$21.3KForm 4
May 21, 2026Weiguo YeChief Operating OfficerSale12,820$6.15$78.8KForm 4
May 20, 2026Weiguo YeChief Operating OfficerSale9,400$6.15$57.8KForm 4
May 19, 2026Weiguo YeChief Operating OfficerSale9,120$6.37$58.1KForm 4
May 18, 2026Weiguo YeChief Operating OfficerSale200$6.62$1.3KForm 4
May 15, 2026Weiguo YeChief Operating OfficerSale13,100$6.65$87.1KForm 4
May 14, 2026Weiguo YeChief Operating OfficerSale15,580$6.91$108KForm 4
May 6, 2026Ying LuoCEOSale10,136$8.04$81.5KForm 4
May 5, 2026Ying LuoCEOSale179$8.01$1.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Weiguo YeChief Operating Officer–$870KJun 18, 2026
Ying LuoChief Executive Officer, Director–$82.9KMay 6, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GYRE short interest

Low short interest. 2.0% of GYRE shares are sold short: about 1 share in 50. Over the last 12 reports the number of shares short went up 34%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.24M GYRE shares were sold short, 2.0% of the shares outstanding, up 16.3% from the report before. At the average daily volume of 157,556 shares, buying them all back would take about 14.2 trading days (days to cover).

Shares short, % of all shares

2.01%May 15Oct 302.19%

Days to cover

14.2May 15Oct 3042.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.24M2.01%+16%157,55614.2
Oct 15, 20261.93M1.73%+0%118,30116.3
Sep 30, 20261.92M1.72%+11%277,1176.9
Sep 15, 20261.73M1.55%+1%90,00719.2
Aug 31, 20261.71M1.53%-2%49,64434.4
Aug 14, 20261.75M1.57%-4%56,23231.1
Jul 31, 20261.82M1.88%-11%48,78037.4
Jul 15, 20262.04M2.11%+12%84,48224.2
Jun 30, 20261.83M1.88%+5%155,11611.8
Jun 15, 20261.74M1.79%+4%94,41018.4
May 29, 20261.67M1.72%-0%94,81317.6
May 15, 20261.68M1.73%+6%92,21018.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

GYRE Therapeutics company events

GYRE Therapeutics filed 19 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 22, 2026LeadershipGyre Therapeutics, Inc. entered into an employment agreement with Ying Luo, Ph.D., to continue to serve as Gyre’s Chief Executive Officer. Filing
  3. Sep 1, 2026AnnouncementShared information with investors. Filing
  4. Aug 26, 2026AnnouncementShared information with investors. Filing
  5. Aug 7, 2026ResultsReleased financial results. Filing
  6. Jul 16, 2026LeadershipThe board of directors of Gyre Therapeutics, Inc. appointed Yue Xiong, Ph.D. as a Class I director of the Company, Maxwell Kirkby as a Class II director of the Company and Claire Weston, Ph.D. as a Class III director of the Company, in each case effective as of August 1, 2026. Filing
  7. Jul 15, 2026ResultsAmended an earlier report. Released financial results. Filing
  8. Jun 16, 2026VoteReported shareholder vote results. Filing
  9. Jun 2, 2026AnnouncementShared information with investors. Filing
  10. May 14, 2026AnnouncementShared information with investors. Filing
  11. May 12, 2026AnnouncementShared information with investors. Filing
  12. May 7, 2026ResultsReleased financial results. Filing
  13. May 4, 2026LeadershipResignation of Directors In accordance with the Merger Agreement, immediately prior to the Effective Time, Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company and any respective committee of the Board to which they were members, and Mr. Ma also resigned from his… Filing
  14. Apr 17, 2026AgreementAmended an earlier report. Of the Original Form 8-K solely to correct the clerical error. Filing
  15. Mar 23, 2026AnnouncementGyre Pharmaceuticals Co., Ltd., Gyre Therapeutics, Inc.’s majority indirectly owned subsidiary, submitted its New Drug Application to the Center for Drug Evaluation of China’s National Medical Products Administration for F351 (Hydronidone), the Company’s lead product candidate, for the treatment of… Filing
  16. Mar 12, 2026AnnouncementShared information with investors. Filing
  17. Mar 12, 2026ResultsReleased financial results. Filing
  18. Mar 2, 2026LeadershipResignation of Directors In accordance with the Merger Agreement, immediately prior to the Effective Time, Thomas Eastling and Songjiang Ma will resign from the Board and any respective committee of the Board to which they were members, and Mr. Ma will also resign from his position as President of… Filing
  19. Jan 5, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

GYRE Therapeutics financials

Famous investors that hold GYRE

1 of the 50 well-known investors we track reported holding GYRE in their latest 13F filing. The largest position is Israel Englander's, worth $148K.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 202620,136$148K0.0%+9%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Gyre Therapeutics, Inc. (GYRE) stock

Who owns the most GYRE stock?

The largest reported owner of Gyre Therapeutics, Inc. (GYRE) is HSG Holding Ltd, with 3.9% of the company. In total, 59 funds and institutions reported holding GYRE at the end of Q2 2026, together about 9% of the shares. See the largest owners.

Are GYRE insiders buying or selling?

In the last 12 months, GYRE insiders reported no open-market purchases and 18 sales worth $953K. The latest trade was on Jun 18, 2026. See every trade.

What is the short interest in GYRE?

As of Oct 30, 2026, 2.24M GYRE shares were sold short, 2.0% of the shares outstanding, up 16.3% from the report before. At the average daily volume of 157,556 shares, buying them all back would take about 14.2 trading days (days to cover). See the history.

Which famous investors hold GYRE?

1 of the 50 well-known investors we track reported GYRE in their latest 13F filing, including Israel Englander. The largest position is worth $148K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.